Novartis Pharma Bangladesh Valsartan brands are not affected by recall

 Dhaka, July 24 (NsNewsWire) — Novartis (Bangladesh) Limited, the leading multinational pharmaceutical company in Bangladesh announced that their valsartan brands – Diovan®, CoDiovan®, Entresto® and Exforge® are not affected for recent Valsartan recall.

Novartis wants to assure general public, healthcare professionals and other concerned stakeholders that the valsartan brands- Diovan®, CoDiovan®, Entresto® and Exforge®, marketed in Bangladesh, are produced using its own research based ‘innovator valsartan’ API, which is not affected.

Novartis produces its research based API for Valsartan only at its own manufacturing plants based in Switzerland and England, maintaining the highest level of quality.

Recent recall of valsartan is being done in 23 countries because an impurity was found during qualification tests of generic valsartan API (Active Pharmaceutical Ingredient) were manufactured by a certain Chinese third party manufacturer.  The impurity was identified as N-Nitrosodimethylamine (NDMA).

Being a leader in pharmaceutical industry, Novartis is committed to ensuring that all our marketed products meet the highest quality standards, which is reflected in their 45 years journey in Bangladesh. Novartis wants to reassure its stakeholders that the physicians and patients can use the mentioned medicines confidently. press release